Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine
Kidney Int
.
2021 Aug;100(2):459.
doi: 10.1016/j.kint.2021.06.005.
Epub 2021 Jun 10.
Authors
Clare Morlidge
1
,
Sally El-Kateb
2
,
Praveen Jeevaratnam
2
,
Barbara Thompson
2
Affiliations
1
Pharmacy Department, Lister Hospital, Stevenage, Hertfordshire, UK. Electronic address: claremorlidge@nhs.net.
2
Renal Department, Lister Hospital, Stevenage, Hertfordshire, UK.
PMID:
34119512
PMCID:
PMC8191285
DOI:
10.1016/j.kint.2021.06.005
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines / adverse effects*
COVID-19*
ChAdOx1 nCoV-19
Humans
Nephrosis, Lipoid* / chemically induced
Recurrence
Substances
COVID-19 Vaccines
ChAdOx1 nCoV-19